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Key Messages

• Gastric electrical stimulation (GES) is a therapeutic option for intractable symptoms of gastroparesis (GP). The

primary objective of this study was to demonstrate an improvement in weekly vomiting frequency (WVF) when
the device was turned ON, relative to when the device was turned OFF during a blinded, 3 month, crossover
phases. The secondary goal was to demonstrate a reduction in symptom scores and to assess changes in quality
of life, gastric emptying, number of days in hospital, and BMI in our ID-GP cohort when receiving active
stimulation for up to 12 months.
• 32 patients with GP of idiopathic origin, majority young women (81%), were implanted with GES. The stimulator was turned ON for 1½ months followed by double-blind randomization to consecutive 3 month crossover
periods with the device either ON or OFF. ON stimulation was followed in unblinded fashion for another 4.5
months. During the unblinded ON period, there was a significant reduction WVF from baseline (61.2%, P <
0.001), and it was followed with median reduction of WVF by 17% (P > 0.10) between ON and OFF phase
of the study. At 1 year, the mean WVF remained decreased by 87%, (P < 0.001), and it was accompanied
by improvements in GP symptoms, gastric emptying and days of hospitalization (P < 0.05).
Importance of the study

• The first massage is that initiation of GES for 6 weeks caused a rapid and significant reduction of symptoms
•
•

which was able to be sustained despite a period of up to 3 months with the device OFF.
Even though, the double blind 3 month periods showed a non-significant reduction in vomiting in the ON vs.
OFF period, at 12 months with ON stimulation, there was a continuous decrease in vomiting symptoms and
days of hospitalizations.
Future placebo-controlled research trials must be initiated at the time of surgery, with ON and OFF phases
being designed in be parallel but not cross-over fashion.

Abstract
Background Gastric electrical stimulation (GES) is a
therapeutic option for intractable symptoms of gastroparesis (GP). Idiopathic GP (ID-GP) represents a
subset of GP. AIMS: A prospective, multicenter,
double-blinded, randomized, crossover study to evalAddress for Correspondence
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uate the safety and efficacy of Enterra GES in the
treatment of chronic vomiting in ID-GP. Methods
Thirty-two ID-GP subjects (mean age 39; 81% F, mean
7.7 years of GP) were implanted with GES. The
stimulator was turned ON for 1½ months followed
by double-blind randomization to consecutive
3-month crossover periods with the device either ON
or OFF. ON stimulation was followed in unblinded
fashion for another 4.5 months. Twenty-five subjects
completed the crossover phase and 21 finished 1 year
of follow-up. Key Results During the unblinded ON
period, there was a reduction in weekly vomiting
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frequency (WVF) from baseline (61.2%, P < 0.001).
There was a non-significant reduction in WVF
between ON vs OFF periods (the primary outcome)
with median reduction of 17% (P > 0.10). Seventy-five
percent of patients preferred the ON vs OFF period
(P = 0.021). At 1 year, WVF remained decreased
(median reduction = 87%, P < 0.001), accompanied
by improvements in GP symptoms, gastric emptying
and days of hospitalization (P < 0.05). Conclusions &
Inferences (i) In this prospective study of Enterra GES
for ID-GP, there was a reduction in vomiting during
the initial ON period; (ii) The double-blind 3-month
periods showed a non-significant reduction in vomiting in the ON vs OFF period, the primary outcome
variable; (iii) At 12 months with ON stimulation,
there was a sustained decrease in vomiting and days
of hospitalizations.
Keywords gastric stimulation, gastroparesis, idiopathic gastroparesis, nausea, vomiting.
Abbreviations: DM, diabetes mellitus; GES, gastric
electrical stimulation; GET, gastric emptying test; GP,
gastroparesis; ID-GP, idiopathic gastroparesis; ID, idiopathic; ITT, intent to treat; PP, per protocol; QOL,
quality of life; SF-36, short form-36; TSS, total symptoms score; WAVESS, Worldwide Anti-vomiting Electrical Stimulation Study; WVF, weekly vomiting
frequency.

INTRODUCTION
Gastroparesis (GP) describes a chronic gastric motility
disorder with delayed gastric emptying and symptoms,
which include early satiety, nausea and vomiting.1–4
Gastroparesis has many causes with diabetic GP being
the classic disorder. However, approximately one third
of GP patients are ‘idiopathic’ (ID) meaning that the
pathogenic basis of the GP condition is mostly
unknown. This unknown aetiology creates a challenge
to their clinical and therapeutic management.5
In the treatment of severe symptoms of drug-refractory GP, there are not many therapeutic options.6,7

Enrollment
and
28 Day Diary

Initial therapies include nutritional modifications,
medications to stimulate gastric emptying and medications to reduce symptoms of nausea and vomiting.
Botulinum toxin injection into the pylorus may provide short-term reduction in symptoms, but placebocontrolled studies have not been favorable.8,9 When
medications fail to control symptoms, interventional
measures to support nutritional status may be
required. Some GP patients refractory to medical
treatment are candidates for gastric electrical stimulation (GES). The Enterra System (Medtronic Inc, Minneapolis, MN, USA) utilizes high frequency (14 Hz;
12 cpm) short pulse width (330 ls) and low-energy
stimulation. This neurostimulation approach with the
Enterra System is FDA approved and has been available
under a Humanitarian Device Exemption (HDE) program since March 2000 for use in the treatment of
chronic, intractable (drug-refractory) nausea and vomiting secondary to GP of diabetic or ID etiology.10
Over the last 11 years, Enterra GES has been used for
treatment of some refractory patients based on its
safety and efficacy profile.11 The improvement of
nausea and vomiting shown in many open-labelled
clinical trials indicates that reduction in GP symptoms
can be achieved.12 The first placebo-controlled multicenter Worldwide Anti-Vomiting Electrical Stimulation Study reported a significant decrease in vomiting
during the double-blind period of 1-month ON compared with the 1-month OFF period following implantation, particularly with diabetic GP.13 With continued
ON stimulation, there was improved quality of life
(QOL) and a modest improvement in gastric retention
at 6 and 12 months of GES. Other non-placebo-controlled publications have confirmed similar outcomes
with a sustained decrease in GP symptoms, nutritional
support, days of hospitalization, which was associated
with improvements in body mass index (BMI) and, in
diabetic GP, better glycemic control.14–18
Due to the paucity of double-blind placebo-controlled
data focused on Enterra GES therapy, this clinical trial
was initiated to evaluate the efficacy and safety of
gastric neurostimulation therapy for severe gastroparetic subjects with ID etiology. The purpose of this clinical
Three
months:
Device ON

Implant

1½ months:
Device ON

Three
months:
Device OFF
4 ½ months:
Device ON

Randomization
Three
months:
Device OFF

Three
months:
Device ON

Figure 1 Study design.
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evaluation was to demonstrate the safety and efficacy of
Enterraâ Therapy in the treatment of chronic, intractable (drug-refractory) nausea and vomiting secondary to
GP of ID etiology. The primary objective was to
demonstrate that there was a reduction in weekly
vomiting frequency (WVF) when the device was turned
ON, relative to when the device was turned OFF during a
blinded crossover phase. The secondary objectives were
as follows: (i) to demonstrate a reduction in symptom
scores when the device is turned ON relative to when
the device was turned OFF, and (ii) to demonstrate a
long-term reduction in WVF at 12 months relative to
baseline. Additional goals included assessment of the
safety of Enterra Therapy, evaluation of the 12-month
responder rate, 12-month change in symptom score, 12month change in QOL, gastric emptying, number of
days in hospital and BMI.

Gastric electrical stimulation therapy in idiopathic gastroparesis

Implantation technique
Study subjects were implanted with the Enterraâ Therapy
system (Model 7425G or Model 3116; Medtronic Inc.). Two
intramuscular leads (Model 4351; Medtronic Inc.) were inserted
into the muscularis propria of the stomach using either laparoscopy or laparotomy as previously described.21 The two leads were
placed 10 cm from the pylorus on the greater curvature of the
stomach and 1 cm apart and were connected to the neurostimulator device placed subcutaneously in the abdominal wall. The
device was programmed to standardized parameters (5 mA,
14 Hz, 330 ls, cycle on 0.1 s, cycle off 5 s) using a programmer
(Model 7432 or Model 8840; Medtronic). During the first
7.5 months, the programming parameters were not changed,
with the exception that the voltage was adjusted based on
impedance to maintain a 5 mA current. Furthermore, the voltage
was set to 0 during the OFF period. After the 7.5 month visit,
programming parameters could be adjusted at the investigator’s
discretion based on the assessment of the subject’s symptoms
status.

Outcome measures
MATERIALS AND METHODS
This was a prospective, multicenter, double-blind, randomized,
controlled, two-period crossover study conducted at eight centres
in the United States under Institutional Review Board approval.
The study design is presented in Fig. 1. The device was turned ON
for the first 1½ months after implant to allow for full recovery
from surgery prior to randomization. At 1½ months, each subject
was randomized in a masked fashion to one of two treatment
arms: three OFF followed by 3 months of stimulation ON. The
subject, physician and study coordinator were blinded to the
stimulation status during the crossover phase. At the end of the
crossover period, the subjects were programmed ON and evaluated at a 12-month follow-up visit and annually thereafter until
study closure (Fig. 1 – detailed study design).

Study subjects
All subjects signed a written informed consent prior to enrollment
in the study. To be eligible for the study, subjects were required to
meet the following inclusion criteria: at least 18 years of age;
symptoms of nausea and vomiting requiring treatment for greater
than 1 year associated with GP of ID etiology unresponsive or
intolerant to prokinetic and antiemetic drug classes tried over a
minimum of 1 month, and on a stable dose of prokinetics for a
minimum of 30 days prior to baseline, unless contraindicated.
Subjects were required to undergo a gastric emptying test (GET)
using the standardized isotope-labelled low-fat egg substitute
meal with imaging out to 4 h19,20 and were considered eligible if
results showed greater than 10% retention at 4 h and/or greater
than 60% at 2 h. All subjects had to be symptomatic and
experience at least seven episodes of vomiting during a seven
consecutive day period as captured on a 28-day baseline diary.
Exclusion criteria included the following: mechanical obstruction; diabetes mellitus (DM); pseudo-obstruction; scleroderma;
amyloidosis; Parkinson’s disease; Muscular Sclerosis; paraneoplastic syndromes; current parathyroid and adrenal disorders;
prior gastric surgery for gastric resection, bariatric surgery,
fundoplication or vagotomy; current primary disorders such as
psychogenic vomiting, eating disorders or swallowing disorders;
chemical dependency; peritoneal dialysis or unstable haemodialysis; and current or planned pregnancy.

Subjects were required to record daily vomiting episodes in a 28day diary to assess WVF prior to each visit. The frequency and
severity of GP symptoms (vomiting, nausea, early satiety, bloating, postprandial fullness, epigastric pain, and epigastric burning)
were assessed using a 5-point symptom interview questionnaire at
baseline and each follow-up visit. The frequency symptom scores
were rated by the patient as 0, absent; 1, rare (1 per week); 2,
occasional (2–3 per week); 3, frequent (4–6 per week); 4, extremely
frequent (≥7 per week). The severity symptom scores were rated as
0, absent; 1, mild (not influencing the normal activities); 2,
moderate (diverting from, but not urging modifications, of usual
activities); 3, severe (influencing usual activities, severely enough
to urge modifications); 4, extremely severe (requiring bed rest).
The sums of the frequency or severity ratings of the seven
symptoms were used as an overall frequency or severity total
symptom score (TSS).
Health-related QOL was assessed at baseline and follow-up
visits using the previously validated short form-36 (SF-36) Health
Status Survey questionnaire, version 1.22 Gastric emptying was
evaluated of a solid meal at baseline and 12 months using a
standardized scintigraphy method and a low-fat test meal.20 Type
of nutritional support (oral, J-tube, G-tube, TPN) and whether or
not it was continuous or intermittent was collected at baseline
and on follow-up visits.
Number of days in the hospital for treatment of GP was
collected at baseline and visits up to 12 months.
Adverse events were monitored throughout the study. All
events were classified using the Medical Dictionary for Regulatory Activities (MedDRA). Cause and severity of each adverse
event was assessed by the principal investigator and adjudicated
by an Adverse Events Committee. The cause of the adverse event
was classified as being ‘device-related’ (the event is caused by a
suspected device malfunction), ‘therapy-related’ (the event is
directly or indirectly caused by the surgical implantation procedure; or is associated with the presence and/or use of the device) or
‘patient-related’ (the event is associated with the subject’s underlying diagnosis or a new diagnosis, unrelated to the device).
Serious adverse events were considered when they resulted in
death, were life threatening, required inpatient hospitalization or
prolongation of existing hospitalization, resulted in persistent or
significant disability or incapacity, or resulted in a congenital
anomaly/birth defect.

© 2013 The Authors.
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Sample size, randomization and blinding
A 25% reduction in WVF when device was ON relative to when
device was OFF was considered to be clinically significant. Based
on 80% power to detect this significant difference with a standard
deviation of 50% (a = 0.05, two-sided), 32 subjects were required
for analysis. To compensate for non-evaluable subjects, a maximum of 75 subjects were allowed to be implanted. Subjects were
randomized by Sponsor at 1 : 1 ratio stratified by center in a block
size of four to have therapy turned ON or OFF at the beginning of
the crossover periods. Randomization assignments were generated
centrally, put into sealed envelopes and sent to authorized
unblinded personnel at the study site prior to the randomization
visit. The subjects, the investigators and the study coordinators
were blinded to the device settings during the crossover period.
Authorized unblinded personnel checked the device status and
programmed the device at follow-up visits during the crossover
period. The record of such an activity was kept in a separate
binder not accessible to the other study-site personnel.

objectives used completed cases and were analysed using a
Wilcoxon Signed Rank test. Probability values were deemed
significant at a level of 0.05. Subjects with a 50% or greater
reduction in WVF at 12 months were defined as responders. A onesided binomial test with a significance level of 0.025 was used to
test whether the responder rate at 12-months was >50%.
Symptom scores (individual and TSS) and SF-36 (eight subscores, Physical Component Summary [PCS], and Mental Component Summary [MCS]) were analysed using either a paired t-test
or Wilcoxon Signed Rank test. Probability values were deemed
significant at a level of 0.05. No adjustments were made for
multiple hypothesis testing.
A Wilcoxon Signed Rank test was used and a significance level
of 0.05 was applied for analyses of additional study measurements. Statistical analysis was performed using SAS version 9.1
(SAS Institute Inc., Cary, NC, USA).

RESULTS
Statistical analysis

Baseline demographics

The primary objective was assessed by the within subject percent
(%) reduction in WVF during ON period relative to OFF period.
The secondary objective of WVF was assessed by the percent
reduction in WVF at 12 months relative to baseline. Both

Thirty-two subjects (81% women) with a mean age of
39 years (range 22–64) and mean BMI of 25.1 kg m 2
(range 14–39) from six sites underwent implant of

Implanted
32

Randomization
27

Completed Crossover Phase
25*
(*Note: 2 subjects were turned ON
early due to medical conditions, 2
subjects had randomization
assignment errors, and 1 subject
had missing diaries)

Completed 12-month Follow-up
Phase
21**
(**Note: 19 finished 12-month visit
and 2 missed 12-month visit)

5 subjects not randomized:
2 withdrew consent
1 noncompliance
1 exited due to study closure
1 missed the randomization visit
and subsequently exited due to
study closure

2 withdrew consent

2 deaths
1 exited due to medical condition
1 exited due to study closure
Figure 2 Subject disposition.
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Median WVF at Baseline and Follow-ups

Median Weekly Vomiting Frequency

20
18

17.25

16
14
12
9.75

10
8
5.5

6

6.38

4

2

2
0
Baseline
n = 32

Figure 3 Weekly vomiting frequency at
baseline and follow-ups.

Enterraâ Therapy between October 2002 and
December 2008. Two additional study sites did not
enroll subjects. Subjects had symptoms of GP for a
mean of 7.7 years (range 1.5–28) prior to enrolment and
a median vomiting frequency of 17.3 episodes per
week. All subjects had delayed gastric emptying with a
median gastric retention of 69% at 2 h and 31% at 4 h.
In total, 10 subjects were receiving nutritional support,
five (16%) enteral (J-tube), four (13%) oral, and one (3%)
Table 1 Results during crossover phase
Variable

N

ON state

WVF*, median
20 6.4 (2.8–17.3)
(interquartile range)
Frequency symptom score†, mean  SD
Vomiting
21
2.38  1.24
Nausea
21
3.29  1.06
Early satiety
21
2.76  1.37
Bloating
21
2.33  1.59
Postprandial fullness 21
2.10  1.26
Epigastric pain
21
2.00  1.38
Epigastric burning
21
1.14  1.42
Total symptom score 21
16.0  6.29
(TSS)
Severity symptom score‡, mean  SD
Vomiting
21
2.10  1.26
Nausea
21
2.38  1.12
Early satiety
21
1.95  1.20
Bloating
21
1.71  1.38
Postprandial fullness 21
1.52  1.03
Epigastric pain
21
1.62  1.28
Epigastric burning
21
0.81  1.08
Total symptom score 21 12.10  5.83
(TSS)

1 1/2-month
n = 25

ON period
n = 20

OFF period
n = 20

12-month
n = 18

parenteral. Two of the five patients with J-tubes
discontinued early from the study (one lost to followup and one subject withdrew consent before implantation), and they were not part of the evaluation of the
study results. Two of the remaining patients were able
to discontinue them during the trial.
For the subjects who were randomized, there were
no significant differences in baseline characteristics
between the two randomized groups.

Subject disposition
OFF state

P-value

9.8 (3.6–25.6)

1.000

2.71
3.48
2.62
2.29
2.38
2.33
1.38
17.19










1.19
0.87
1.50
1.62
1.53
1.46
1.66
6.98

0.823
0.910
0.352
0.555
0.230
0.969
0.031
0.932

2.29
2.71
1.95
1.86
2.00
1.90
1.10
13.81










1.15
1.15
1.36
1.53
1.48
1.34
1.37
6.95

0.838
0.936
0.609
0.539
0.176
0.840
0.063
0.556

*WVF, Weekly Vomiting Frequency.
†
For each individual symptom frequency score, 0 = absent and
4 = extremely frequent (≥7 per week), total symptom frequency score
is the sum of all the individual symptom scores.
‡
For each individual symptom severity score, 0 = absent and
4 = extremely severe (requiring bed rest), total symptom severity score
is the sum of all the individual symptom scores.

Among the 32 subjects enrolled and implanted, five
were not randomized. There were 25 subjects who
completed the crossover phase and 21 subjects who
completed the 12-month visit (Fig. 2 – full details on
subject flow).

Initial 1½-month results
To assess the impact of the initial ON period prior to
randomization, a post hoc analysis of WVF at 1½ month
compared with baseline was completed for subjects
who provided diary data at 1½-month visit (n = 25),
regardless of their subsequent follow-up status of this
1½-month visit. The median reduction in WVF of
61.2% was statistically significant (P < 0.001) at
1½ months compared with baseline with a median
WVF of 17.3 episodes at baseline and 5.5 episodes at
1½ months (Fig. 3). Among these 25 subjects, only
eight did not respond with greater than 25% reduction
in WVF during the 6-week initial active stimulation.
The mean TSS for frequency was also statistically
significantly decreased (14.6%, P < 0.001) during this
period of time from 21.4 to 16.1 points.

© 2013 The Authors.
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Table 2 Results of weekly vomiting frequency at 12-month follow-up
Analysis method

N

Baseline

12-Month

Median per cent reduction

P-value

Completed case
Per-protocol
ITT

18
19
27

17.3 (10–36.8)
17 (6–36.8)
21.8 (9.5–36.8)

2 (0.3–8.5)
2.3 (0.3–8.5)
4 (1.5–23)

87.1% ( 80.4–100%)
85.3% ( 80.4–100%)
80.9% ( 102.6–100%)

<0.001
<0.001
0.003

Results are presented as median (interquartile range).
Table 3 Other study results at 12-month follow-up
Variable

N

Baseline

Frequency symptom score, mean  SD
Vomiting
19
3.32  0.95
Nausea
19
3.79  0.54
Early satiety
19
3.26  0.81
Bloating
19
3.05  1.27
Postprandial
19
3.42  0.90
fullness
Epigastric pain 19
2.84  1.30
Epigastric
19
2.05  1.75
burning
TSS
19 21.74  5.16
Severity symptom score, mean  SD
Vomiting
19
2.95  0.85
Nausea
19
3.21  0.79
Early satiety
19
2.58  0.90
Bloating
19
2.21  1.08
Postprandial
19
2.89  0.99
fullness
Epigastric pain 19
2.37  1.21
Epigastric
19
1.84  1.61
burning
TSS
19 18.05  6.34
SF-36 health survey, mean  SD
PF
19 36.61  12.16
RP
19 29.81  5.19
BP
19 32.84  7.76
GH
19 32.58  9.89
VT
19 30.37  9.03
SF
19 26.57  11.62
RE
19 38.15  12.76
MH
19 34.90  14.15
PCS
19 32.66  8.8
MCS
19 34.11  11.67
% Gastric retention, median (interquartile
@2h
16 63.5 (56.5–74%)
@4h
16 26 (16.5–37%)
Days in hospital, 19 2 (0-9)
median
(interquartile
range)
19 26.96
BMI, median
(19.05–31.92)
(interquartile
range)

12-Month

1.68
2.68
2.00
1.79
1.84







P-value

1.42
1.29
1.37
1.81
1.54

0.001
0.005
0.001
0.005
0.001

1.63  1.67
1.37  1.64

0.002
0.154

13.00  7.92

<0.001







1.07
0.89
1.26
1.58
1.22

<0.001
<0.001
0.001
0.044
<0.001

1.47  1.50
1.16  1.42

0.011
0.114

10.26  7.09

<0.001

42.79  13.31
37.63  12.3
37.37  15.25
34.21  10.31
38.47  11.82
38.85  12.82
44.25  12.89
39.32  11.33
37.86  13.28
41.27  12.29
range)
49 (40.5–63.5%)
16.5 (4.8–37.5%)
0 (0–0)

0.032
0.006
0.150
0.520
0.003
<0.001
0.069
0.020
0.043
0.001

1.37
1.68
1.58
1.53
1.47

24.74
(22.25–31.61)

0.016
0.236
0.006

0.768

TSS, Total symptom score; PF, Physical functioning; RP, Role
physical; BP, Bodily pain; GH, General health; VT, Vitality; SF, Social
functioning; RE, Role emotional; MH, Mental health; PCS, Physical
component summary; MCS, Mental component summary.

Crossover phase
Of those subjects who completed the crossover phase,
20 provided diary data to assess the WVF during ON
and OFF states. Among these 20 subjects, 12 were
randomized to ON–OFF and eight to OFF–ON

sequence of the GES stimulation. The data analyses
are provided in Table 1 and Fig. 3. As already presented, most subjects showed a large reduction in WVF
from baseline to 1½ months at which time they were
randomized to be either ON or OFF for period of
3 months each. During the double-blind crossover
phase, the median WVF of 6.4 episodes during the
ON state was less than the 9.8 episodes during the OFF
state (Table 1). The within-patient median reduction
in WVF from ON to OFF during this crossover phase,
the primary outcome variable, was 17.3% (P = 1.0). Of
interest is that 15 of 20 (75%) of the study patients
were females and they had an 18.4% greater median
reduction in vomiting during ON vs OFF, whereas five
males were 37.5% worse during ON vs OFF. The
frequency and severity of the TSS also did not show
statistical differences between ON and OFF states
(P = 0.933 and 0.556 respectively).
At the end of the crossover phase, subjects were
surveyed as to which state they preferred. Both the
patients and the investigators were blinded to the
treatment sequence. Of the 20 subjects, 15 (75%)
preferred the ON state and five (25%) preferred the OFF
state. The proportion of subjects that preferred the ON
state (75%) was statistically significantly different
from 50% as expected by chance (binomial exact test,
one-sided P = 0.021).

12-month follow-up phase
There were 19 subjects who finished the 12-month
follow-up visit and provided required study data. One
of the 19 subjects had missing diary data for WVF. The
results of analysis are presented in Tables 2 and 3.
We have observed that the WVF at 12 months
decreased significantly when compared with baseline,
with a median reduction of 87.1% (P < 0.001). The
median WVF was 17.3 episodes at baseline and two
episodes at 12 months. In this period, a responder was
defined as having a 50% or greater reduction in WVF
from baseline to 12 months, and there were 17
responders (94.4%, P < 0.001) in our cohort.
Two sensitivity analyses, intent-to-treat (ITT) and
per-protocol (PP) were performed to address the missing WVF data at 12 months. The ITT analysis

820
© 2013 The Authors.
Neurogastroenterology & Motility published by John Wiley & Sons Ltd.

Volume 25, Number 10, October 2013

included all the subjects who were randomized.
Per-protocol analysis included all subjects who finished 12 months of follow-up, including one subject
with missing diary data. The imputation method of
last-observation-carried-forward was applied to adjust
for the missing data for the PP and ITT analyses. Only
those observations made while the device was turned
ON were carried forward. Per-protocol and ITT analyses revealed a median reduction of 85.3% (P < 0.001)
and 80.9% (P = 0.003), respectively, from baseline to
12 months.
The mean TSS frequency and severity scores were
significantly decreased from baseline to 12 months
(P < 0.001). Six individual symptom scores, specifically
vomiting, nausea, early satiety, bloating, postprandial
fullness and epigastric pain, were also decreased
significantly from baseline to 12 months for both
frequency and severity symptom scores (P < 0.05).
There was no significant reduction in the frequency
or severity symptom scores of epigastric burning at
12 months (P = 0.154 and 0.114 respectively).
Quality of life scores at 12 months was also
improved from baseline. Statistically significant
improvements were observed in the PCS and MCS
scores (P = 0.043 and P < 0.001 respectively). Increased
values in sub-scores were observed in all eight domains
of the SF-36 survey, with statistically significant
improvements in the physical functioning, role physical, vitality, social functioning and mental health
domains (P < 0.05).
Annualized median days in the hospital decreased
from a median of 2 days at baseline to 0 days at
12 months (P = 0.006).
There were three patients with J-tubes and one other
patient on parenteral feeding, who continued in the
study and they all had improvement in either WVF or
symptom scores or both and their results were
included in the final analysis. Two of the three patients
were able to have their J-tubes removed while the
parenteral nutrition-dependent patient had less frequent supplements.
BMI and weight measurements were stable over the
follow-up period (Table 3).
Gastric emptying overall improved at 12 months
with stimulation. Two-hour scintigraphy gastric emptying (n = 16) was significantly improved at 12 months
with a median retention at 2 h of 49.0% (interquartile
rage 40.5–63.5%) compared with 63.5% (interquartile
rage 56–74%) at baseline (P = 0.016). There was a
numerical improvement in 4-h gastric emptying with a
median retention at 4 h of 16.5% (interquartile rage
4.8–37.5%) compared with 26.0% (interquartile rage
16.5–37%) at baseline (P = 0.236). Overall 10 subjects
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(62%) had an improved rate of emptying, with six
subjects (38%) normalizing their gastric emptying
(<10% retention at 4 h) at 12-month visit. There was
a non-significant difference in the grading of symptoms
between the group of patients whose gastric emptying
showed mild retention at 4 h (11%) vs those with
profound delays in emptying (>40%) at the 12 month
follow-up.
After the crossover phase, from 7½ month to
12 months of follow-up, stimulation parameters could
be adjusted by the investigators: Pulse width remained
at 330 ls, except for two patients (10%) who were
programmed at a 450 ls. The Pulse Rate remained at
14 Hz in all patients; Voltage is calculated from
current and impedance. For the patients whose programming data were available at both 7½- and 12month visits, the mean current was 6.2 mA at 7½month visit and there was a mean increase of 1.3 mA
at the 12-month visit, reflecting these small
adjustments.

Adverse events
A total of 170 adverse events were collected in the
study. Of these, 145 (85.3%) were patient-related
events. There were 24 (14.1%) therapy- or devicerelated events, of which three were serious. Among the
three serious events, there was one paresthaesia, one
lead migration/dislodgement and one migration of
neurostimulator. The serious event of paresthaesia
was described as the subject experiencing a midline
‘jolting’ sensation every 15 min, which was effectively
resolved with device re-programming, and no residual
effects. Overall, two of 32 subjects (6.3%) required
surgical intervention for the previously mentioned lead
migration/dislodgment and the neurostimulator migration. There was one ID subject who died of unknown
cause. As the cause of death is unknown, the relatedness could not be determined by the investigator or the
Adverse Event Committee. None of the implanted
subjects developed infection of the leads and/or pocket
housing the implantable pulse generator. Moreover, no
explants of the Enterra System were reported during
12 months of observation.
Among the 145 patient-related events, 70 were
serious events. Signs and symptoms of GP, such as
nausea and vomiting, were considered an adverse event
only when they resulted in hospitalization for more
than 23 h. Gastroparesis-related hospitalizations
(coded as ‘impaired gastric emptying’ in MedDRA)
occurred 41 times in 11 subjects, comprising 58.6% of
all serious patient-related adverse events. Other serious
patient-related adverse events reported more than once
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were related to hypertension,3 infection or complication of the feeding tube2 and headache.2
There was a mortality rate of 6.3% (two of 32
subjects) at 1 year. The cause of death for one of the ID
subjects was sudden cardiac arrest. The cause of death
for the other subject remains undetermined, as the
clinical-site personnel had been unable to obtain any
elucidating information from public records or the
family. Therefore, there is no information to indicate
whether this death was device- or therapy-related.

DISCUSSION
The primary objective of this study of gastric electric
stimulation in patients with refractory nausea and
vomiting from ID-GP was to demonstrate an improvement in WVF when the device was turned ON, relative
to when the device was turned OFF during a blinded
crossover phase. Our primary outcome measure
showed only a non-significant trend (17% reduction)
in the improvement in WVF during the ON compared
with the OFF double-blind period. Of interest, the
reduction in WVF, which occurred in the first
1½ months after initiation of gastric stimulation therapy, was sustained throughout the crossover period and
subsequent follow-up evaluations with more than 80%
improvement in frequency of vomiting being observed
at 12 months.
One implication of our observations is that the rapid
and significant induction of symptom improvement in
the first 6 weeks was able to be sustained, despite a
period of up to 3 months with the device OFF. Subjects
reported that when the device was ON, they experienced a median of 17.3% less episodes of vomiting per
week than when device was OFF. This positive effect
from being ON compared with OFF was very prominent in female patients who represented 75% of the
study participants while not pronounced in male
subjects. In addition, there was a statistically significant personal preference for the ON vs OFF state of
gastric stimulation with 75% of patients favoring the
symptoms response while being in the ON state.
This study revealed that the initial reduction in
vomiting frequency and overall GP symptoms with
gastric electric stimulation was able to be sustained
over the year follow-up period. This major favorable
effect was associated with improvements in QOL and a
significant reduction in hospitalization days, thus
secondary outcome goals were met in this ID group
as was the case in the diabetic GP trial and also
reported in the literature.23,24 Mortality rate at
12 months in this idiopathic gastroparesis (ID-GP)
study was lower than in the corresponding diabetic

GP trial, 6.3% vs 12.7% respectively.25 Obviously, the
clinical complications of ongoing DM provide different
and more serious comorbidity and challenges.
Gastric emptying was also numerically improved
over the 1-year study with GES, with 38% of patients
normalizing GET results, which was higher than
previously observed in diabetic GP where 25%
returned to normal.13,25 This outcome could be consistent with the hypothesis that time, and adequate
treatment, may regenerate gastric tissue and nerves,
and reverse the injury/damage secondary to a viral or
bacterial gastroenteritis that is suspected as the
etiology in many ID-GP patients.26,27
There were many challenges and factors, which
influenced the recruitment, execution and outcome of
this study, resulting in a severely underpowered data
analysis limiting the interpretation of the results. The
major contributing factors, which hampered the
recruitment of ID cohort of GP patients were as
follows: (i) the lengthy insurance approval process for
the preauthorization of therapy; (ii) availabilities of
Enterra Therapy through FDA approved HDE application, allowing patients to have access to the therapy
without participating in the double-blind research
study; (iii) A small number of centres6 were willing
to conduct the protocol, compared to many (>90) other
centres where Enterra was available through HDE
application.
We believe that lack of a ‘washout period’ between
any of the ON and OFF phases compromised the data
we obtained and conceivably masked the GES effects.
In addition, the question concerning ‘placebo effect’
and the presence of ‘cell/tissue memory phenomenon’
or ‘carry over effect’ induced by continuous electrical
stimulation for the first 1½ months, and in half the
subjects up to 4½ months, remains a confounding
aspect of this trial as was the case in the similarly
designed trial in diabetic GP.25 The influence of
placebo or regression to the mean in this electrical
stimulation trial is a possibility to explain the longterm improvement. However, the patients studied
were chronically symptomatic and refractory to all
other treatments. These patients were recruited at six
different academic centers and historically required
many admissions to their respective Emergency
Departments or hospitals in the months preceding
their entry into this research trial, thus providing
evidence against ‘a placebo’ effect that might be
sustained for 1 year. The memory or imprinting effect
of 6 or 18 weeks of continuous stimulation suggests
that any future trials require randomization from the
time of surgical implant using a parallel study design
without a crossover arm. Another option would be to
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have an initial single-blind OFF period after surgery of
1–2 months followed by randomization to either ON
or OFF and no crossover phase.
One another suggestion for a future study is also to
consider establishing more precise scales, indices and
questionnaires to appreciate changes in symptoms of
enrolled subjects. The newer condition-specific, validated tools and scales such as PAGI-SYM, PAGI-QOL
and GCSI have been incorporated into GP research in
the last few years, but they were not available at the
time the double-blind Enterra studies were being conducted.28,29 The 5-point (0–4) symptom interview questionnaire utilized in this study was not refined enough
to distinguish differences; for example, as related to
frequency of GP symptoms. The highest rating of four
points on the 5-point scale was marked as an extremely
frequent – meaning ≥7 episodes of vomiting/week.
However, subjects could be vomiting anywhere from 8
to >100 times per week and would grade those events
equally as extremely severe and extremely frequent by
marking ‘4 points’ regardless. We believe that this scale
may have camouflaged many important observations
and made interpretation of the results more difficult.
In conclusion, although the double-blinded ON/OFF
GES treatment did not achieve its primary outcome
objective, the 12-month clinical outcome data from
this clinical trial of Enterra GES support the efficacy
and safety of Enterra therapy for subjects diagnosed
with severe, medication-unresponsive GP of ID etiology. Improvements in study design and symptoms
assessment are suggested for future randomized controlled clinical trials with Enterra Therapy in GP, so
that questions of clinical efficacy can be accurately
addressed.
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